Low-Dose Oral Minoxidil and Topical Minoxidil: Consensus Recommendations for Managing Male and Female Pattern Hair Loss in Hair Transplant Patients Using a Modified Delphi Process

    March 2026 in “ Figshare ”
    Gupta, Aditya K., Talukder, Mesbah, Williams, Greg, Abdelhamid, Haitham, Akiska, Yagiz Matthew, Alpeter, David, Boden, Scott A., Erfan, Randa, Farjo, Bessam, Farjo, Nilofer, Gabel, Steven, Harris, James A., Hekimian, Karl J., Keene, Sharon, Krejci-Manwaring, Jennifer, Leonard, Robert T., Nader, Luis A., Pathomvanich, Damkerng, Perez-Meza, David, Rogers, Nicole E., Rose, Paul T., Schambach, Marie A., Shapiro, Ronald L., Singh, Mayank, Stough, Dow B., True, Robert H., Wasserbauer, Sara M., Welter, Ryan J.
    Image of study
    TLDR Low-dose oral and topical minoxidil are recommended for managing hair loss in transplant patients, with specific doses and precautions.
    This study provides consensus-based recommendations for the use of low-dose oral minoxidil (LDOM) and topical minoxidil in managing male and female pattern hair loss, particularly around hair transplant surgery. An international panel of hair transplant surgeons used a modified Delphi process to agree on guidelines, including checking body weight and blood pressure before starting LDOM, with recommended starting doses of 1.25–2.5 mg/day for men and 0.625–1.25 mg/day for women. Clinical response is expected within 4–6 months, and treatment can continue long-term if effective. LDOM can be taken 1–3 days post-surgery, while topical minoxidil can be applied 7–14 days after transplant. Minoxidil should be avoided during pregnancy and breastfeeding. These guidelines aim to standardize the integration of LDOM and topical minoxidil into hair transplant patient care.
    Discuss this study in the Community →